RESUMO
To investigate whether infliximab [Ib], an inhibitor of tumor necrosis factor alpha [TNF-alpja], prevents cisplatin [Cis] -induced nephrotoxicity. The study was performed in the Department of Internal Medicine, RecepTayyip Erdogan University, Rize, Turkey, between November 2012 and May 2013. Thirty male Wistar albino rats were divided into 3 groups, a control group, a Cis group, and a Cis+Ib group. The animals of the Cis group were injected with a single dose [7 mg/kg] of Cis intraperitoneally. The animals of the Cis+Ib group were injected with a single dose [7 mg/kg] of Ib 72 hours prior to Cis injection. The TNF-a, interleukin-1 beta [IL-1J3], nitric oxide [NO] and adenosine deaminase [ADA] levels of the Cis group were higher than both the control group TNF-alpha [p<0.001], IL-la [p<0.001], NO [p<0.001] and ADA [p<0.001], and the Cis+Ib group TNF-alpha [p<0.001], IL-1[3 [p<0.001], NO [p<0.001], and ADA [f=0.003]. Histopathological examination revealed extensive damage in the Cis group, while the damage in the Cis+Ib group was lower. While the carbonic anhydrase II [CA-II] level of the Cis group was lower than both groups, it was similar in the Cis+Ib and the control groups. Infliximab acts against Cis-induced nephrotoxicity by a strong inhibition of TNF-alpha. Additionally, the combination of these 2 drugs does not obviously change the level of CA-II